Trial Profile
A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC 681239) and Bendamustine in Patients With Untreated Follicular Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Bendamustine; Ofatumumab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 08 Mar 2024 Planned End Date changed from 24 May 2019 to 7 Mar 2025.
- 31 May 2020 Results establishing if BMB add value in assessing response or identify distinct progression free (PFS) or overall survival (OS) outcomes in a large, multicenter, multi-trial cohort presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2019 Results assessing Ofarumumab and Bendamustine vs. Ofatumumab, Bendamustine, and Bortezomib in previously untreated patients with follicular lymphoma published in the Cancer